Sio Capital Management
NEW YORK, NYfiles as Sio Capital Management, LLC
$584m in 57 US stocks at the end of 30 June 2026. The top 10 are 50.1% of the money. It changed about 44.8% of the portfolio this quarter.
Value
$584m
Stocks
57
Top 10 share
50.1%
Turnover
44.8%
What changed this quarter
New
Bought for the first time this quarter.
- Allogene TherapeuticsALLO4.7% of the fund
- Globus MedicalGMED4.1% of the fund
- IDEAYA BiosciencesIDYA3.1% of the fund
- Cigna GroupCI2.7% of the fund
- ViatrisVTRS2.6% of the fund
- Regeneron PharmaceuticalsREGN1.9% of the fund
- Bristol-Myers SquibbBMY1.9% of the fund
- MedtronicMDT1.9% of the fund
- Helus PharmaHELP1.5% of the fund
- Tango TherapeuticsTNGX1.1% of the fund
- Aveanna Healthcare HoldingsAVAH0.5% of the fund
- ArtivionAORT0.2% of the fund
- Neuroone Medical TechnologiesNMTC<0.1% of the fund
- Enveric BiosciencesENVB<0.1% of the fund
- QT Imaging HoldingsQTI<0.1% of the fund
Added
Bought more of a stock they already held.
- Anteris Technologies GlobalAVR9.4% of the fund+3%
- CencoraCOR8.4% of the fund+72%
- GSKGSK3.9% of the fund+13%
- Tyra BiosciencesTYRA3.8% of the fund+15%
- Oruka TherapeuticsORKA2.9% of the fund+34%
- Sanofi SASNY2.7% of the fund+52%
- Zimmer Biomet HoldingsZBH1.9% of the fund+110%
- Senseonics HoldingsSENS1.6% of the fund+1276%
- Relmada TherapeuticsRLMD1.2% of the fund+4%
Cut
Sold some of their stake.
- MaximusMMS6.6% of the fund-7%
- Waystar HoldingWAY3.3% of the fund-44%
- IconICLR2.6% of the fund-71%
- Rapport TherapeuticsRAPP2.2% of the fund-16%
- Abbott LaboratoriesABT2.0% of the fund-31%
- CelcuityCELC2.0% of the fund-43%
- Vir BiotechnologyVIR1.9% of the fund-28%
- EyePointEYPT1.5% of the fund-14%
- ANI PharmaceuticalsANIP1.4% of the fund-63%
- Protara TherapeuticsTARA1.3% of the fund-2%
- Aquestive TherapeuticsAQST1.1% of the fund-23%
- Dianthus TherapeuticsDNTH1.0% of the fund-84%
- Sionna TherapeuticsSION1.0% of the fund-57%
- Ocular TherapeutixOCUL0.9% of the fund-44%
- Zenas BioPharmaZBIO0.9% of the fund-37%
- Bright Minds BiosciencesDRUG0.9% of the fund-14%
- PMV PharmaceuticalsPMVP0.6% of the fund-14%
- Ovid TherapeuticsOVID0.5% of the fund-20%
- ImmunomeIMNM0.5% of the fund-25%
- AN2 TherapeuticsANTX0.4% of the fund-19%
- Adagio Medical HoldingsADGM<0.1% of the fund-46%
Sold out
Sold their entire stake.
- Corcept TherapeuticsCORT-100%
- LivaNovaLIVN-100%
- EmbectaEMBC-100%
- Abivax SAABVX-100%
- HaemoneticsHAE-100%
- TeleflexTFX-100%
- Biomarin PharmaceuticalBMRN-100%
- Structure TherapeuticsGPCR-100%
- BiohavenBHVN-100%
- Monopar TherapeuticsMNPR-100%
- Crinetics PharmaceuticalsCRNX-100%
- Edgewise TherapeuticsEWTX-100%
- COMPASS PathwaysCMPS-100%
- QuidelOrthoQDEL-100%
- Replimune GroupREPL-100%
- OrganonOGN-100%
- Disc MedicineIRON-100%
- Integra Lifesciences HoldingsIART-100%
- ProQR TherapeuticsPRQR-100%
- Shoulder InnovationsSI-100%
- Kymera TherapeuticsKYMR-100%
- Context TherapeuticsCNTX-100%
- HyperfineHYPR-100%
- Foghorn TherapeuticsFHTX-100%
- Terns Pharmaceuticals-100%
Holdings
- GSKGSK
- Share
- 3.9%
- Value
- $23m
- Shares
- 436,700
+13%
- Sanofi SASNY
- Share
- 2.7%
- Value
- $16m
- Shares
- 364,200
+52%
- Cross Ctry Healthcare
- Share
- 2.5%
- Value
- $15m
- Shares
- 1,098,393
Held
- Helus PharmaHELP
- Share
- 1.5%
- Value
- $9m
- Shares
- 1,300,000
New
- Bright Minds BiosciencesDRUG
- Share
- 0.9%
- Value
- $5m
- Shares
- 73,952
-14%
- Rocket Pharmaceuticals
- Share
- <0.1%
- Value
- $1,480
- Shares
- 400,000
Held
- Humacyte
- Share
- <0.1%
- Value
- $477
- Shares
- 49,998
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Anteris Technologies GlobalAVR | 9.4% | $55m | 5,545,984 | +3% |
| CencoraCOR | 8.4% | $49m | 173,588 | +72% |
| MaximusMMS | 6.6% | $38m | 715,267 | -7% |
| Allogene TherapeuticsALLO | 4.7% | $28m | 13,323,431 | New |
| Globus MedicalGMED | 4.1% | $24m | 301,816 | New |
| GSKGSK | 3.9% | $23m | 436,700 | +13% |
| Tyra BiosciencesTYRA | 3.8% | $22m | 695,315 | +15% |
| Waystar HoldingWAY | 3.3% | $19m | 925,834 | -44% |
| IDEAYA BiosciencesIDYA | 3.1% | $18m | 480,383 | New |
| Oruka TherapeuticsORKA | 2.9% | $17m | 177,118 | +34% |
| Cigna GroupCI | 2.7% | $16m | 57,750 | New |
| Sanofi SASNY | 2.7% | $16m | 364,200 | +52% |
| IconICLR | 2.6% | $15m | 88,186 | -71% |
| ViatrisVTRS | 2.6% | $15m | 954,299 | New |
| Cross Ctry Healthcare | 2.5% | $15m | 1,098,393 | Held |
| Rapport TherapeuticsRAPP | 2.2% | $13m | 307,657 | -16% |
| Abbott LaboratoriesABT | 2.0% | $12m | 128,656 | -31% |
| CelcuityCELC | 2.0% | $12m | 110,022 | -43% |
| Zimmer Biomet HoldingsZBH | 1.9% | $11m | 131,445 | +110% |
| Regeneron PharmaceuticalsREGN | 1.9% | $11m | 18,000 | New |
| Bristol-Myers SquibbBMY | 1.9% | $11m | 193,500 | New |
| MedtronicMDT | 1.9% | $11m | 142,500 | New |
| Vir BiotechnologyVIR | 1.9% | $11m | 1,075,274 | -28% |
| Senseonics HoldingsSENS | 1.6% | $9m | 1,592,692 | +1276% |
| EyePointEYPT | 1.5% | $9m | 623,130 | -14% |
| Helus PharmaHELP | 1.5% | $9m | 1,300,000 | New |
| ANI PharmaceuticalsANIP | 1.4% | $8m | 97,305 | -63% |
| Protara TherapeuticsTARA | 1.3% | $7m | 1,921,872 | -2% |
| Relmada TherapeuticsRLMD | 1.2% | $7m | 1,003,562 | +4% |
| Tango TherapeuticsTNGX | 1.1% | $7m | 208,500 | New |
| Aquestive TherapeuticsAQST | 1.1% | $6m | 1,486,175 | -23% |
| Dianthus TherapeuticsDNTH | 1.0% | $6m | 59,254 | -84% |
| Sionna TherapeuticsSION | 1.0% | $6m | 127,808 | -57% |
| Ocular TherapeutixOCUL | 0.9% | $5m | 539,493 | -44% |
| Zenas BioPharmaZBIO | 0.9% | $5m | 208,557 | -37% |
| Bright Minds BiosciencesDRUG | 0.9% | $5m | 73,952 | -14% |
| OnKure TherapeuticsOKUR | 0.8% | $5m | 1,078,965 | Held |
| SavaraSVRA | 0.7% | $4m | 617,675 | Held |
| PMV PharmaceuticalsPMVP | 0.6% | $4m | 2,634,137 | -14% |
| Aveanna Healthcare HoldingsAVAH | 0.5% | $3m | 369,036 | New |
| Ovid TherapeuticsOVID | 0.5% | $3m | 1,005,334 | -20% |
| ImmunomeIMNM | 0.5% | $3m | 124,168 | -25% |
| AN2 TherapeuticsANTX | 0.4% | $3m | 529,933 | -19% |
| Serina TherapeuticsSER | 0.3% | $2m | 1,000,000 | Held |
| Aligos TherapeuticsALGS | 0.3% | $2m | 327,237 | Held |
| iBioIBIO | 0.3% | $2m | 904,268 | Held |
| Xilio TherapeuticsXLO | 0.3% | $1m | 152,464 | Held |
| ArtivionAORT | 0.2% | $1m | 48,481 | New |
| BridgeBio Oncology TherapeuticsBBOT | 0.2% | $995,385 | 130,628 | Held |
| TELA BioTELA | <0.1% | $477,225 | 636,300 | Held |
| Adagio Medical HoldingsADGM | <0.1% | $455,461 | 698,989 | -46% |
| Neuroone Medical TechnologiesNMTC | <0.1% | $251,612 | 82,767 | New |
| Enveric BiosciencesENVB | <0.1% | $248,400 | 180,000 | New |
| Modular MedicalMODD | <0.1% | $117,855 | 26,190 | Held |
| QT Imaging HoldingsQTI | <0.1% | $62,011 | 15,236 | New |
| Rocket Pharmaceuticals | <0.1% | $1,480 | 400,000 | Held |
| Humacyte | <0.1% | $477 | 49,998 | Held |
Options (2)
- SELLAS Life Sciences GroupSLS
- Type
- Put
- Value
- $18m
- Contracts
- 1,230,700
- Hims & Hers HealthHIMS
- Type
- Call
- Value
- $3m
- Contracts
- 75,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| SELLAS Life Sciences GroupSLS | Put | $18m | 1,230,700 |
| Hims & Hers HealthHIMS | Call | $3m | 75,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 134.2% since 30 June 2025.
Where the money is
Health care79.5%
Industrials8.1%
Technology3.3%
Other9.1%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.